This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Pulmonary Valve Disorders폐동맥판장애

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: I37 (Pulmonary valve disorders) | Special Copayment Reduction: V192 (Special copayment reduction for heart disease: 5% copayment for up to 30 days from the registration date)
B. SynonymsPulmonary valve stenosis, pulmonary valve insufficiency, nonrheumatic pulmonary valve disease, pulmonic stenosis, pulmonary regurgitation, pulmonary valve insufficiency
C. Adult onsetPulmonary valve stenosis is mainly congenital and detected in childhood but can persist uncorrected into adulthood. Pulmonary valve regurgitation becomes a problem mainly in adults after repair of tetralogy of Fallot.
1. HistoryHistory of the recognition of pulmonary valve stenosis, development of balloon valvuloplasty (1982), introduction of transcatheter pulmonary valve implantation (TPVI)
2. CausesStenosis: congenital (most cases), carcinoid, Rubinstein-Taybi syndrome, etc.; regurgitation: after tetralogy of Fallot repair, congenital, pulmonary hypertension
3. GeneticsPulmonary valve stenosis associated with Noonan syndrome (PTPN11 variants), Alagille syndrome (JAG1), and Williams syndrome (7q11.23 deletion)
4. General epidemiologyPulmonary valve stenosis accounts for 7–12% of all congenital heart disease; isolated pulmonary valve disease is about 2–3% of adult valvular disease
5. PathophysiologyStenosis: right ventricular pressure overload → right ventricular hypertrophy; regurgitation: right ventricular volume overload → right ventricular dilation → dysfunction
6. SymptomsMild stenosis: asymptomatic; severe: exertional dyspnea, syncope, chest pain; regurgitation: asymptomatic early, symptoms of right heart failure later
7. SignsSystolic ejection murmur (pulmonic area), wide fixed splitting of S2, Graham Steell murmur (in regurgitation), elevated jugular venous pressure
8. ScreeningEchocardiographic screening; in adults after tetralogy of Fallot repair, regular cardiac MRI to follow right ventricular function and regurgitation
9. DiagnosisEchocardiography (pressure gradient, regurgitant volume), cardiac MRI (right ventricular volume and function), cardiac catheterization (when severity assessments are discordant)
10. TreatmentStenosis: balloon valvuloplasty (first-line); regurgitation: transcatheter pulmonary valve implantation (Melody, SAPIEN 3) or surgical replacement
11. PrognosisMild stenosis has a good prognosis; right ventricular function recovers after timely intervention; long-term prognosis in tetralogy of Fallot depends on the severity of regurgitation
12. PreventionRegular follow-up after early repair of congenital heart disease; surveillance for regurgitation after tetralogy of Fallot repair and selection of the optimal timing of surgery
13. ReferencesKan JS et al. Percutaneous balloon valvuloplasty: a new method for treating congenital pulmonary valve stenosis … and 9 other papers

1. History

Recognition of pulmonary valve disease began with pathological anatomical descriptions in the late 19th century. Congenital pulmonary valve stenosis was described in 1888 by Fallot as one of the components of tetralogy of Fallot, and the clinical significance of isolated pulmonary valve stenosis subsequently became increasingly apparent. In 1948, Brock successfully performed surgical pulmonary valvotomy, demonstrating for the first time that this disease could be corrected surgically.

In 1982, Kan et al. performed the first successful transcatheter balloon pulmonary valvuloplasty (BPV), bringing revolutionary change to the treatment of pulmonary valve stenosis. BPV is a technique that widens the narrowed valve via a catheter without cardiopulmonary bypass and subsequently became established as the first-line treatment, replacing open-heart surgery. Currently, BPV is established worldwide as the standard treatment for suitable forms of pulmonary valve stenosis (typical dome-shaped stenosis).

The long-term problem of residual pulmonary valve regurgitation after tetralogy of Fallot repair came to the fore in the 1990s. As patients who had undergone tetralogy of Fallot repair reached adulthood, right ventricular dilation and dysfunction emerged as major problems, leading to the need for pulmonary valve replacement. In 2000, Bonhoeffer et al. performed the first successful transcatheter pulmonary valve implantation (TPVI), after which the Melody valve (Medtronic) and SAPIEN valve (Edwards Lifesciences) systems were developed and approved and are now widely used in clinical practice.


2. Causes

The cause of pulmonary valve stenosis is mostly congenital. Typical congenital pulmonary valve stenosis is most commonly a form in which fused leaflets form a dome (about 80%). A dysplastic pulmonary valve is often associated with Noonan syndrome and responds poorly to balloon dilation. Carcinoid syndrome forms fibrous plaques on the pulmonary and tricuspid valves through secretion of serotonin and other vasoactive substances, causing both stenosis and regurgitation. Post-radiotherapy changes, metastatic tumors, etc. are also rare causes of stenosis.

The most common cause of pulmonary valve regurgitation is iatrogenic regurgitation occurring after repair of tetralogy of Fallot. When the valve commissures are incised or a transannular patch is inserted to enlarge the right ventricular outflow tract during surgery, residual regurgitation occurs. Secondary regurgitation due to pulmonary hypertension, damage after infective endocarditis, congenital absence of the pulmonary valve (absent pulmonary valve syndrome), etc. are also among the causes. Regurgitation can also occur from annular dilation due to idiopathic pulmonary artery dilation.


3. Genetics

Many genetic syndromes associated with pulmonary valve stenosis are known. Noonan syndrome is the single-gene syndrome most commonly accompanied by pulmonary valve dysplasia; it is caused mainly by variants in the PTPN11 gene (encoding the SHP-2 phosphatase) and is inherited in an autosomal dominant manner. Congenital heart disease is present in about 50–62% of patients with Noonan syndrome, of which pulmonary valve dysplasia accounts for about 20–50%.

Alagille syndrome is an autosomal dominant disorder caused by variants in the JAG1 (Jagged1) gene and is often accompanied by peripheral pulmonary artery stenosis and pulmonary valve stenosis. Williams syndrome is caused by a microdeletion of the long arm of chromosome 7 (7q11.23) and is characterized by supravalvular aortic stenosis and peripheral pulmonary artery stenosis due to deletion of the elastin (ELN) gene. Known genetic factors for tetralogy of Fallot (ToF) include the 22q11.2 microdeletion (associated with DiGeorge syndrome) and variants in transcription factors such as NKX2-5 and GATA4.

Genome-wide association studies (GWAS) of sporadic pulmonary valve stenosis have reported associations with loci near cardiac development-related genes such as GATA4, HAND1, and NKX2-5. When a genetic syndrome is suspected, chromosomal microarray or clinical whole-genome testing is recommended.


4. General epidemiology

Pulmonary valve stenosis is a relatively common congenital heart disease, accounting for about 7–12% of all congenital heart disease. Isolated pulmonary valve stenosis occurs in about 0.6–0.8 per 1,000 live births. If pulmonary outflow tract stenosis as a component of complex congenital heart disease such as tetralogy of Fallot is included, the prevalence is higher. Sex differences are minimal, but there are reports that it is slightly more common in women.

Among adult valvular diseases, pulmonary valve disease is relatively rare (about 2–3%), but at adult congenital heart disease (ACHD) centers, residual pulmonary valve regurgitation after tetralogy of Fallot repair is treated as an important problem. The prevalence of tetralogy of Fallot is about 0.3–0.4 per 1,000 live births, and as patients who underwent repair reach adulthood, the population living with pulmonary valve regurgitation continues to grow. According to transcatheter pulmonary valve implantation (TPVI) registry data, several thousand procedures are currently performed annually worldwide.


5. Pathophysiology

The key pathophysiology in pulmonary valve stenosis is right ventricular pressure overload due to right ventricular outflow tract (RVOT) obstruction. The more severe the stenosis, the higher the pressure the right ventricle must generate to eject blood into the pulmonary artery, and as a compensatory response right ventricular hypertrophy (concentric right ventricular hypertrophy) progresses. When pressure overload becomes chronic, right ventricular diastolic function declines, the right ventricular preload (right atrial pressure) needed to maintain cardiac output eventually rises, and right heart failure ultimately develops. In addition, elevated right atrial pressure can cause a right-to-left shunt when a patent foramen ovale (PFO) is present, resulting in cyanosis.

Pulmonary valve regurgitation imposes volume overload on the right ventricle. Initially, the right ventricle adapts to the increased preload with volume overload dilation (eccentric hypertrophy), and systolic function is maintained for a considerable period. However, when chronic severe regurgitation persists, right ventricular dilation worsens and the ventricular geometry becomes spherical, with a gradual decline in systolic function. Right ventricular dilation causes tricuspid annular dilation and functional tricuspid regurgitation, forming a vicious cycle that further worsens right heart failure. Once right ventricular function has declined, complete recovery may not be possible even after pulmonary valve replacement, so timely replacement is important.


6. Symptoms

The symptoms of pulmonary valve stenosis are proportional to the severity of stenosis. Mild stenosis (peak right ventricle–pulmonary artery gradient <36 mmHg) is mostly asymptomatic and discovered incidentally. In moderate stenosis (gradient 36–64 mmHg), exertional dyspnea and fatigue may occur. In severe stenosis (gradient ≥64 mmHg), markedly reduced exercise tolerance, syncope (especially with exertion), chest pain, and cyanosis (with a right-to-left shunt) may occur. In severe cases, symptoms of right heart failure (leg edema, ascites, hepatomegaly) develop.

Pulmonary valve regurgitation runs a long course without symptoms. In adults after tetralogy of Fallot repair, most initially notice a gradual decline in exercise tolerance. As severe regurgitation progresses, arrhythmias (atrial fibrillation, ventricular tachycardia), palpitations on exertion, symptoms of right heart failure (leg edema, abdominal distension), syncope, etc. appear. The risk of sudden death is also increased in patients with tetralogy of Fallot, emphasizing the need for continued follow-up care.


7. Signs

The characteristic auscultatory finding of pulmonary valve stenosis is a systolic ejection murmur heard at the upper left sternal border (pulmonic area). The murmur is preceded by a separate ejection click, which characteristically decreases on inspiration (respiratory variation of a pulmonary ejection click). P2 may be diminished or absent, and wide splitting of S2 is observed. In severe stenosis, a right ventricular gallop (S4) due to right heart hypertrophy may be palpable at the lower sternal border.

The characteristic finding of pulmonary valve regurgitation is the Graham Steell murmur, a high-pitched diastolic decrescendo murmur heard at the upper left sternal border. It typically appears in secondary regurgitation due to pulmonary hypertension, whereas the regurgitant murmur at normal pulmonary artery pressure is lower-pitched and shorter. A systolic heave at the lower left sternal border and a parasternal heave due to right ventricular dilation are observed.


8. Screening

Screening for pulmonary valve disorders is done mainly by echocardiography when abnormal auscultation findings are detected or congenital heart disease is suspected. When a murmur is heard in the pulmonic area, transthoracic echocardiography is the first-line test. Echocardiography to evaluate the pulmonary valve is recommended in all patients diagnosed with or suspected of related genetic syndromes such as Noonan syndrome and Alagille syndrome.

In adult patients who have undergone tetralogy of Fallot repair (adult congenital heart disease, ACHD), regular follow-up including cardiac MRI is strongly recommended. Cardiac MRI can accurately quantify right ventricular volumes (RVEDV, RVESV), right ventricular ejection fraction, and pulmonary regurgitant fraction and is a key tool for deciding the timing of transcatheter pulmonary valve implantation. Cardiac MRI follow-up every 1–2 years after tetralogy of Fallot repair is generally recommended, and the follow-up interval is shortened when right ventricular dilation is identified.


9. Diagnosis

Transthoracic echocardiography (TTE) is the first-line test for diagnosing pulmonary valve disorders. Doppler is used to assess the peak systolic right ventricle–pulmonary artery gradient and pulmonary regurgitation. Severity classification of pulmonary valve stenosis: mild (peak gradient <36 mmHg, peak velocity <3 m/s), moderate (gradient 36–64 mmHg), severe (gradient ≥64 mmHg). The severity of pulmonary regurgitation is assessed by the width of the regurgitant jet, pressure half-time, holodiastolic flow reversal, etc.

Cardiac MRI is the standard test for quantitative assessment of pulmonary regurgitation and measurement of right ventricular function. A regurgitant fraction (RF) of ≥25–40% is considered clinically significant regurgitation, and right ventricular dilation criteria (RVEDVI ≥150–160 mL/m², RVESVI ≥80–90 mL/m²) are used to decide the timing of replacement. Cardiac catheterization is performed when noninvasive tests are discordant or for anatomical evaluation in complex congenital heart disease. Pulmonary angiography and pressure measurement confirm the exact anatomy of the stenotic site and the pressure gradient.


10. Treatment

The first-line treatment of pulmonary valve stenosis is transcatheter balloon pulmonary valvuloplasty (BPV). In typical dome-shaped stenosis, BPV has excellent long-term outcomes and has been shown to be as effective as surgery. Indications for the procedure are all symptomatic moderate or more severe stenosis, or, even if asymptomatic, a peak right ventricle–pulmonary artery gradient ≥40 mmHg (or peak velocity ≥3 m/s). Stenosis due to a dysplastic valve (associated with Noonan syndrome) or carcinoid responds poorly to BPV, and surgical replacement is more appropriate.

In pulmonary valve regurgitation, transcatheter pulmonary valve implantation (TPVI) or surgical pulmonary valve replacement is performed when indicated. Indications for replacement are symptomatic severe regurgitation or, even if asymptomatic, right ventricular dysfunction (RVEF <45%), progressive right ventricular dilation (RVEDVI ≥150 mL/m²), accompanying severe tricuspid regurgitation, or sustained atrial fibrillation or ventricular tachycardia. The Melody valve (Medtronic) and SAPIEN 3 (Edwards) are FDA-approved transcatheter pulmonary valves used for implantation within existing conduits or previous bioprosthetic valves. Surgical replacement is chosen when a transcatheter approach is anatomically difficult or when concomitant surgery is needed.


11. Prognosis

Mild pulmonary valve stenosis has a very favorable natural history. Progression to severe stenosis or development of symptoms is rare, and most patients have a normal or near-normal life expectancy. Patients who undergo timely BPV often show normal right ventricular function and exercise tolerance on long-term follow-up.

Pulmonary valve regurgitation after tetralogy of Fallot repair is an important factor affecting long-term prognosis. Right ventricular dilation due to chronic severe regurgitation is associated with right ventricular dysfunction, arrhythmias, and the risk of sudden death. Timely pulmonary valve replacement induces right ventricular reverse remodeling and reduces the risk of arrhythmias and death, but recovery is incomplete when severe right ventricular dysfunction is already present. Therefore, performing replacement before right ventricular dysfunction progresses irreversibly is the key determinant of prognosis.


12. Prevention

Because pulmonary valve stenosis is mostly congenital in origin, primary prevention is difficult. However, when there is a family history of related genetic syndromes (Noonan syndrome, Alagille syndrome, etc.), neonatal and pediatric echocardiographic screening should be used to ensure early diagnosis and timely treatment. To prevent pulmonary valve involvement in carcinoid syndrome, early diagnosis of the underlying neuroendocrine tumor and suppression of vasoactive substance secretion with somatostatin analog (octreotide) therapy are important.

Surgical techniques are continuously being improved to minimize the development of pulmonary regurgitation after tetralogy of Fallot repair. Residual regurgitation can be reduced by minimizing the use of transannular patches or applying valve-sparing outflow tract reconstruction techniques. After repair, performing pulmonary valve replacement at the optimal time before right ventricular dysfunction progresses, through regular follow-up including cardiac MRI, is key to preventing complications.


13. References

  1. Kan JS, White RI Jr, Mitchell SE, Gardner TJ. Percutaneous balloon valvuloplasty: a new method for treating congenital pulmonary valve stenosis. New England Journal of Medicine. 1982;307(9):540-542. DOI: 10.1056/NEJM198208263070907. PMID: 7099921.

  2. Bonhoeffer P, Boudjemline Y, Saliba Z, et al. Percutaneous replacement of pulmonary valve in a right-ventricle to pulmonary-artery prosthetic conduit with valve dysfunction. Lancet. 2000;356(9239):1403-1405. DOI: 10.1016/S0140-6736(00)02844-0. PMID: 11052583.

  3. Harrild DM, Berul CI, Cecchin F, et al. Pulmonary valve replacement in tetralogy of Fallot: impact on survival and ventricular tachycardia. Circulation. 2009;119(3):445-451. DOI: 10.1161/CIRCULATIONAHA.108.775221. PMID: 19139385.

  4. Frigiola A, Tsang V, Bull C, et al. Biventricular response after pulmonary valve replacement for right ventricular outflow tract dysfunction. Circulation. 2008;118(14 Suppl):S182-S190. DOI: 10.1161/CIRCULATIONAHA.107.756825. PMID: 18824771.

  5. Warnes CA, Williams RG, Bashore TM, et al. ACC/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease. Circulation. 2008;118(23):e714-e833. DOI: 10.1161/CIRCULATIONAHA.108.190015. PMID: 18997169.

  6. Stout KK, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease. Journal of the American College of Cardiology. 2019;73(12):e81-e192. DOI: 10.1016/j.jacc.2018.08.1029. PMID: 30121239.

  7. Lurz P, Coats L, Khambadkone S, et al. Percutaneous pulmonary valve implantation: impact of evolving technology and learning curve on clinical outcome. Circulation. 2008;117(15):1964-1972. DOI: 10.1161/CIRCULATIONAHA.107.735779. PMID: 18378614.

  8. Nollert G, Fischlein T, Bouterwek S, et al. Long-term survival in patients with repair of tetralogy of Fallot. Journal of the American College of Cardiology. 1997;30(5):1374-1383. DOI: 10.1016/S0735-1097(97)00318-6. PMID: 9350940.

  9. Lee C, Kim YM, Lee CH, et al. Outcomes of pulmonary valve replacement in 170 patients with chronic pulmonary regurgitation after relief of right ventricular outflow tract obstruction. Journal of the American College of Cardiology. 2012;60(11):1005-1014. DOI: 10.1016/j.jacc.2012.04.049. PMID: 22858081.

  10. Morray BH, McElhinney DB, Cheatham JP, et al. Risk of infective endocarditis after transcatheter pulmonary valve replacement using the Medtronic Melody valve. Circulation: Cardiovascular Interventions. 2012;5(1):84-90. DOI: 10.1161/CIRCINTERVENTIONS.111.966762. PMID: 22338002.